PMGC Stock In Shambles: Down -38% With 9-Day Losing Streak
PMGC (ELAB) stock hit day 9 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -38% return. The company has lost about $1.7 Mil in value over the last 9 days, with its current market capitalization at about $2.8 Mil. The stock remains 94.1% below its value at the end of 2024. This compares with year-to-date returns of 15.9% for the S&P 500.
PMGC’s recent streak reflects deep investor concern, fueled by a staggering -361.33% quarterly net income drop to -$2.59M and pervasive bearish sentiment. Its tiny $2.86M market cap amplifies volatility, making it highly sensitive to negative financial news.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.For quick background, ELAB provides physician-dispensed, modernized aesthetic skincare solutions focused on innovation and advanced research in the field.
Comparing ELAB Stock Returns With The S&P 500
- CSCO Stock: Two Signals Pointing The Same Way
- Decoding AVGO Stock’s Premium Valuation
- What Could Push NVDA Stock Higher From Here?
- Cash Machine Trading Cheap – Inspire Medical Systems Stock Set to Run?
- Five-Year Tally: AT&T Stock Delivers $58 Bil Gain
- Years of Rewards: $43 Bil From Caterpillar Stock
The following table summarizes the return for ELAB stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ELAB | S&P 500 |
|---|---|---|
| 1D | -14.0% | -0.2% |
| 9D (Current Streak) | -38.5% | -0.2% |
| 1M (21D) | -39.9% | 1.2% |
| 3M (63D) | -41.9% | 3.2% |
| YTD 2025 | -94.1% | 15.9% |
| 2024 | -99.4% | 23.3% |
| 2023 | 24.2% | |
| 2022 | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 105 S&P constituents with 3 days or more of consecutive gains and 41 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 31 | 31 |
| 4D | 41 | 4 |
| 5D | 24 | 4 |
| 6D | 3 | 2 |
| 7D or more | 6 | 0 |
| Total >=3 D | 105 | 41 |
Key Financials for PMGC (ELAB)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-1.1 Mil | $-3.7 Mil |
| Net Income | $-4.3 Mil | $-6.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $0 | $0.3 Mil |
| Operating Income | $-1.0 Mil | $-2.2 Mil |
| Net Income | $-0.6 Mil | $-2.6 Mil |
The losing streak ELAB stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.